Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 study of weekly subcutaneous marstacimab prophylaxis in children with severe hemophilia A or moderately severe to severe hemophilia B, with or without inhibitors
MOH_2023-03-26_012382Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of marstacimab in hemophilia A and hemophilia B (HB), sponsored by Pfizer. Started Feb 2023; status: recruiting.
02
Drugs
marstacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on MOH_2023-03-26_012382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-26_012382.